Ligand Pharmaceuticals, Inc. (LGND)
ROA
Obliczenia
|
2023/Q4 (31 gru 2023) |
2023/Q3 (30 wrz 2023) |
2023/Q2 (30 cze 2023) |
2023/Q1 (31 mar 2023) |
2022/Q4 (31 gru 2022) |
2022/Q3 (30 wrz 2022) |
2022/Q2 (30 cze 2022) |
2022/Q1 (31 mar 2022) |
||
|---|---|---|---|---|---|---|---|---|---|
| Zysk netto (ttm) | w tys. USD | 52 154 | 16 481 | 27 158 | 23 973 | -33 361 | -21 292 | -7 973 | 23 647 |
| Aktywa razem | w tys. USD | 787 216 | 769 226 | 758 105 | 811 076 | 762 668 | 1 050 600 | 1 076 290 | 1 105 180 |
| ROA | 6,63% | 2,14% | 3,58% | 2,96% | -4,37% | -2,03% | -0,74% | 2,14% |
2023/Q4 obliczenia
ROA = Zysk netto (ttm) ÷ Aktywa razem
= $52 154K ÷ $787 216K
= 6,63%
Analiza porównawcza
2023/Q4
Nazwa spółki
Symbol
ROA
Ligand Pharmaceuticals, Inc.
LGND
6,63%
Amphastar Pharmaceuticals Inc
AMPH
9,09%
Arcus Biosciences Inc
RCUS
-28,04%
Catalyst Pharmaceuticals Inc
CPRX
15,19%
Collegium Pharmaceutical Inc
COLL
4,21%
Dynavax Technologies Corp.
DVAX
-0,64%
Innoviva Inc
INVA
14,45%
Ironwood Pharmaceuticals Inc
IRWD
-212,76%
Medifast Inc
MED
32,08%
Myriad Genetics, Inc.
MYGN
-22,97%
Xencor Inc
XNCR
-13,23%